Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
This article was originally published in The Pink Sheet Daily
Bristol/Sanofi blockbuster label was quietly updated two months ago to include precautionary statement and pharmacogenomic data about non-responders to Plavix. That label dovetails with Lilly's initial positioning of prasugrel.
You may also be interested in...
Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Circulation study shows prasugrel metabolism unaffected by marker for Plavix non-response. Data won’t surprise FDA, but what will be the regulatory response?